Vitamin D supplementation: much ado about nothing

Abstract

The scientific interest and the number of papers dealing with vitamin D supplementation has greatly grown in the last decades. Unfortunately, expert consensus on many clinical aspects of this topic is still lacking. In addition, data coming from recent clinical trials and meta-analyses seem to strongly put into doubt the real benefit of vitamin D supplementation, on both skeletal and extra-skeletal outcomes. This is further confusing since they seem to completely contradict the considerable body of evidence provided from previous epidemiological studies. This paper aims to analyze these new data in order to shed light onto the debated issues.

摘要

在过去的几十年中, 有关补充维生素D的科学兴趣和论文数量大大增加。但不幸的是, 专家对这一主题的许多临床方面仍然缺乏共识。此外, 来自最新临床试验和荟萃分析的数据似乎强烈质疑补充维生素D对骨骼和骨骼外结局的真正益处。由于它们似乎完全与先前的流行病学研究提供的大量证据相矛盾, 因此更加令人困惑。本文旨在对这些新数据进行分析, 以阐明存在争议的问题。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Keywords:

• Vitamin D
• osteoporosis
• meta-analysis
• supplementation

Disclosure statement

Davide Gatti reports personal fees from Abiogen, Amgen, Janssen-Cilag, Mundipharma and Pfizer, outside the submitted work.

Francesco Bertoldo reports personal fees from: Abiogen, Amgen, Chiesi, Janssen, Grunenthal, Astellas, outside the submitted work.

Giovanni Adami has no conflict of interest to declare.

Ombretta Viapiana reports personal fees from: Abbvie, Novartis, MSD, Biogen, Fresenius Kabi, UCB, Eli-Lilly.

Stefano Lello has no conflict of interest to declare.

Maurizio Rossini reports personal fees from AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Novartis, Pfizer, Sanofi, Sandoz and UCB, outside the submitted work.

Angelo Fassio reports personal fees from: Abiogen and Novartis, outside the submitted work.